INTRODUCTION:

Quality by Design (QbD) is a systematic approach to pharmaceutical development that focuses on designing and understanding processes to ensure consistent product quality. It was introduced by the International Conference on Harmonisation (ICH) through guidelines like ICH Q8 (Pharmaceutical Development), Q9 (Quality Risk Management), and Q10 (Pharmaceutical Quality System).

The principles of QbD are grounded in Dr. Joseph M. Juran’s quality management theories, aiming to integrate quality from the very beginning of product development, rather than relying on post-manufacturing checks. Quality by Design (QbD) first appeared in the 1980s as a systematic approach to pharmaceutical development, emphasising the necessity of building quality into goods rather than testing for it later. Key milestones in its progress include the introduction of ICH Q8 (2005) on pharmaceutical development, ICH Q9 (2006) on quality risk management, and ICH Q10 (2008) on pharmaceutical quality systems, all of which reinforced a science-based, risk-driven approach to product quality assurance^1-3.

The primary elements of QbD include defining the Quality Target Product Profile (QTPP), which outlines the desired characteristics of the final product. Identifying Critical Quality Attributes (CQAs) is another crucial step to determine which characteristics must be controlled to maintain product quality. The next step involves identifying Critical Process Parameters (CPPs), which are the process variables that have a significant impact on CQAs. Risk management is also vital in QbD to proactively assess and minimize risks throughout the development and manufacturing process.The FDA and EMA have played important roles in promoting QbD principles, with the FDA implementing them into its regulatory framework as part of the 2004 Pharmaceutical cGMPs for the 21st Century project. Their support has influenced worldwide regulatory processes, promoting a more proactive, science-based approach to product development and quality assurance in international markets^4,5. The relevance of QbD to the pharmaceutical industry lies in its ability to enhance product understanding, increase efficiency, reduce variability, and ensure compliance with regulatory standards. By implementing QbD principles, pharmaceutical companies can achieve higher product quality, lower costs, and quicker market release times⁶. An extension of QbD, Analytical Quality by Design (AQbD) focuses specifically on the development and validation of analytical methods. AQbD ensures that analytical procedures are robust, reliable, and capable of producing accurate and consistent results across the product lifecycle. AQbD includes defining an Analytical Target Profile (ATP), which sets the criteria that the analytical method must meet. Risk assessment in AQbD helps identify and mitigate potential sources of unpredictability. The development of the method is done using systematic approaches such as design of experiments (DoE), ensuring a thorough understanding of how various factors affect the method’s performance. Method validation is essential to ensure that the procedure is consistent and meets the ATP criteria, and continuous monitoring ensures its ongoing robustness^4-7. The purpose of the review is to provide an in-depth analysis of both QbD and AQbD within the pharmaceutical industry. It highlights the principles, methodologies, and benefits of these approaches, with an emphasis on how they impact product quality, regulatory compliance, and operational efficiency. Case studies demonstrating successful QbD and AQbD applications, along with discussions on the challenges and future directions for these approaches, will be covered. Additionally, regulatory perspectives and guidelines for the adoption of QbD and AQbD will be examined. QbD improves sustainability in pharmaceutical manufacturing by focussing on process optimisation, which minimises waste, energy consumption, and raw material usage. This strategy not only enhances product quality, but it also promotes more ecologically friendly and efficient manufacturing techniques^4-5.

AQbD significantly improves method understanding, robustness, and regulatory compliance. It offers advantages over traditional methods, which often rely on trial and error. Traditional method development may involve testing and adjusting techniques based on empirical knowledge, which can be time-consuming and may miss potential risks. In contrast, AQbD uses a more scientific, systematic approach with risk assessments, DoE, and continuous monitoring. By identifying and addressing risks early, AQbD ensures robust and reliable methods that align with regulatory standards. This leads to smoother regulatory approval processes, reduces revalidation needs, and optimizes lifecycle management. AQbD builds on the foundation of QbD by incorporating a more tailored, risk-based approach to design and development, ensuring consistent product quality through a deeper understanding of the processes and their variables^8,9. Pharmaceutical companies adopting AQbD principles can develop scientifically sound, robust analytical methods that comply with regulatory standards, ultimately resulting in high-quality products and operational efficiency¹⁰.

Analytical Target Profile (ATP):

The Analytical Target Profile (ATP) is a key concept in Analytical Quality by Design (AQbD) that outlines the criteria an analytical method must meet to ensure its suitability for its intended purpose. Similar to the Quality Target Product Profile (QTPP) in product development, the ATP focuses on the performance standards for analytical procedures. It serves as a guide throughout the method development, validation, and lifecycle management processes. The ATP plays several crucial roles in AQbD, including guiding method development by setting specific performance standards, serving as a benchmark for method validation, and providing a framework for continuous monitoring and improvement. It also supports risk management by identifying critical method parameters and potential risks, allowing for proactive risk mitigation strategies^11,12. Establishing an ATP requires careful consideration of the method's purpose, performance criteria, and regulatory expectations. This includes identifying the method's objective (e.g., measuring potency or impurities), determining Critical Quality Attributes (CQAs) to be assessed, and specifying performance criteria such as accuracy, precision, and sensitivity. Regulatory guidelines (e.g., ICH, USP) must be reviewed to ensure alignment with industry standards. A risk assessment is also essential to identify potential sources of variability and establish control strategies^12-14. For example, in a potency assay for an Active Pharmaceutical Ingredient (API), the ATP would define acceptable accuracy, precision, and sensitivity parameters. Similarly, for impurity profiling, the ATP would specify criteria like recovery accuracy and the limit of detection. By defining the ATP, pharmaceutical companies ensure that analytical methods are robust, reliable, and compliant with regulatory standards throughout the product lifecycle¹³.

Critical Analytical Attributes (CAAs) and Critical Method Parameters (CMPs):

Critical Analytical Attributes (CAAs) and Critical Method Parameters (CMPs) are key to ensuring analytical method performance. CAAs, identified through the Analytical Target Profile (ATP) and regulatory criteria, directly affect accuracy, precision, sensitivity, specificity, and robustness. CMPs, identified through risk assessments, influence CAAs and method performance. Well-controlled CMPs ensure consistent method execution. For example, in High-Performance Liquid Chromatography (HPLC) for impurity profiling, CAAs include impurity resolution and retention time, while CMPs involve column temperature and flow rate. In UV-Vis Spectroscopy for potency assays, CAAs focus on absorbance accuracy, with CMPs including wavelength selection and sample preparation. Proper identification and control of CAAs and CMPs ensure reliable, compliant results^14-17.

Risk Assessment and Management:

Risk assessment plays a crucial role in Analytical Quality by Design (AQbD) by identifying, evaluating, and mitigating risks in analytical processes. It involves determining potential causes of variability, evaluating their impact on method performance, and developing strategies to control risks. Tools like Failure Modes and Effects Analysis (FMEA) prioritize risks based on severity, occurrence, and detectability, while Fishbone Diagrams help identify root causes. Managing risks involves implementing control measures for critical method parameters, monitoring performance, and continuously improving methods based on feedback. Effective risk management ensures reliable analytical methods that consistently meet quality standards. The risk management process in QbD and AQbD focusses on discovering, assessing, and reducing potential risks to product quality using systematic methodologies. Tools such as FMEA (Failure Mode and Effects Analysis) and Fishbone Diagrams are used to identify important failure spots and root causes, allowing teams to address risks proactively and optimise design and production processes^16-18.

Design of Experiments (DOE):

Importance of DOE in AQbD:

Structured Optimization: DOE facilitates the systematic identification and optimization of important parameters influencing analytical methods, resulting in better method performance and reliability.

Efficiency: By applying statistical methodologies to analyse the effects of numerous factors at the same time, the number of trials required is reduced, saving time and resources.

Enhanced Understanding: Provides insights into the interactions of various factors and their effects on technique performance, allowing for more control and resilience.

Steps in Conducting DOE for Method Development

Define Objectives:

Clearly define the experiment's objectives, such as improving procedure accuracy, precision, or sensitivity.

Select Factors and Levels:

Identify key variables (e.g., temperature, pH, concentration) and determine the levels to be tested.

Design the Experiment:

Identify essential variables (e.g., temperature, pH, concentration) and the values to be tested.

Conduct Experiments:

Execute the experiments as planned, ensuring accurate and consistent data gathering.

Analyze Data:

Use statistical analysis to assess the outcomes, discover relevant components and relationships, and select the best circumstances.

Optimize and Validate:

Based on the analysis, fine-tune and validate the approach to ensure it meets the performance requirements.

Examples of DOE Applications in Analytical Methods

HPLC Method Development: Optimizing factors such as mobile phase composition, column temperature, and flow rate to improve resolution and peak shapes.

UV-Vis Spectroscopy: Choosing an optimal wavelength, path length, and sample concentration helps improve sensitivity and accuracy in absorbance measurements.

GC Method Development: To improve peak separation and detection limits, fine-tune parameters such as the oven temperature program, carrier gas flow rate, and injection volume.

Using Design of Experiments (DOE) in pharmaceutical testing allows for the systematic discovery and optimization of critical elements impacting analytical techniques. DOE improves method performance, accuracy, and reproducibility by investigating and measuring the impact of variable interactions on outcomes. This improves test result consistency, makes better use of resources, and assures that analytical methodologies fulfill regulatory quality control criteria. Finally, DOE leads to higher-quality pharmaceutical products and more dependable testing procedures^17-19.

Method Optimization and Design Space:

In Analytical Quality by Design (AQbD), the Design Space is a multidimensional range of parameters and conditions where an analytical method consistently performs well, ensuring robustness and meeting quality requirements. The purpose of the design space is to establish acceptable limits for critical method parameters, ensuring reliable performance under various conditions¹⁹. To optimize methods, strategies like Parameter Screening (using Design of Experiments, DOE), Response Surface Methodology (RSM) for modeling parameter correlations, and Iterative Testing for fine-tuning parameters are employed. Risk Assessment helps evaluate the impact of parameter variations on method robustness²⁰. Identifying essential parameters, creating models to comprehend their effect on performance, and establishing boundaries for reliable outcomes are all part of establishing the design space. Validation and robustness testing inside the design area are part of verification, which is followed by continuous monitoring to modify limitations as necessary. Creating and confirming the design space guarantees that procedures consistently fulfill quality criteria under predetermined circumstances²¹.

Method Validation and Lifecycle Management:

Traditional Validation is a one-time, static process aimed at ensuring a method meets established standards at a specific moment. It focuses on empirical data and often requires extensive testing without addressing variability or robustness, with limited scope on individual parameters. In contrast, AQbD-Based Validation is dynamic and systematic, emphasizing the understanding and control of critical method parameters (CMPs) and their impact on performance. It focuses on method behavior across varying conditions, incorporating risk assessment and design space. This validation is more comprehensive, adaptable, and continuously evaluated, with adjustments made based on ongoing performance monitoring and feedback^8,17,22.

Continuous Method Performance Monitoring and Lifecycle Management:

Continuous Monitoring is essential to ensure that analytical methods remain within the defined design space and meet quality standards over time. Techniques like control charts, trend analysis, and periodic reviews help detect deviations early and ensure consistent performance²³. Lifecycle Management involves optimizing the method from development through routine use and future adjustments. This includes periodic reviews, revalidation when necessary, updates based on new data or regulatory changes, and continuous improvement based on performance monitoring^23,24.

Examples of AQbD in Method Validation:

HPLC Method for Drug Analysis: AQbD creates a design space for parameters like mobile phase composition, flow rate, and column temperature, validating performance within these ranges.

UV-Vis Spectroscopy for Potency Assay: The method considers wavelength, path length, and sample concentration effects, with a design space ensuring consistent absorbance results.

GC Method for Residual Solvent Analysis: AQbD establishes a design space for oven temperature, carrier gas flow rate, and injection volume, ensuring robustness and accuracy within these limits.

By applying AQbD principles, method validation becomes more adaptable and ensures sustained reliability and effectiveness throughout the method’s lifecycle^22-26.

Regulatory Considerations:

Regulatory authorities expect AQbD approaches to be grounded in a solid scientific understanding of analytical methods, including the identification and management of critical method parameters. The AQbD process must be thoroughly documented, covering design space definitions, risk assessments, and validation results. Methods should consistently perform within the defined design space under various conditions and meet regulatory standards for accuracy, precision, and reliability^18,27.

Key Guidelines Include:

ICH Q8 (Pharmaceutical Development): Provides guidelines for applying AQbD in pharmaceutical processes, emphasizing design space and process variable impacts on product quality.

ICH Q9 (Quality Risk Management): Focuses on identifying, assessing, and managing risks in method development to ensure robustness.

ICH Q10 (Pharmaceutical Quality System): Supports continuous improvement and lifecycle management using AQbD principles.

Regulatory agencies like the FDA and EMA align with ICH guidelines, stressing the importance of comprehensive validation, design space, and ongoing monitoring for method compliance^4,8,24.

Case Studies of Regulatory Submissions Involving AQbD:

Case Study 1: HPLC Method for a New Drug Application (NDA)

Background:

A pharmaceutical company submitted an NDA using an HPLC method developed with AQbD principles.

Approach:

Defined a design space for mobile phase composition and column temperature, including a detailed risk assessment and method validation within the design space.

Outcome:

The submission was approved, with regulators noting the method’s robust performance and comprehensive AQbD approach.

Case Study 2:

Potency Assay for an Oncology Drug

Background:

The company utilized AQbD to develop a UV-Vis spectroscopic assay for potency testing of an oncology drug.

Approach:

Established a design space for wavelength and sample concentration, conducted a thorough risk assessment, and validated the method across the design space.

Outcome: The regulatory submission was successful, with the method’s robustness and scientific approach receiving positive feedback from the regulatory agency.

Case Study 3:

GC Method for Residual Solvent Testing

Background:

AQbD principles were applied to develop a gas chromatography method for testing residual solvents in a new drug product.

Approach:

Defined a design space for oven temperature, carrier gas flow rate, and injection volume. The method was validated to demonstrate performance within this space.

Outcome:

The submission was accepted, with regulators appreciating the detailed documentation and effective use of AQbD principles to ensure method reliability.

Regulatory agencies expect a rigorous, well-documented approach to AQbD, ensuring that analytical methods are robust, reliable, and compliant with industry standards ^25,26,28.

Challenges and Future Directions:

Common Challenges in Implementing AQbD:

Complexity of Implementation: AQbD requires a deep understanding of method parameters, risk management, and design space, making it complex and time-consuming. This may lead to increased development time and costs, particularly for organizations new to AQbD. Data Management and Analysis: Managing large datasets from DOE and risk assessments can be challenging and require advanced tools and expertise. Inadequate analysis may result in an incomplete understanding of method behavior and design space. Regulatory Acceptance: Differences in interpretations across agencies can cause confusion and delays in regulatory approvals. Resource Constraints: Some organizations may struggle to fully implement AQbD due to limited resources. Integration with Existing Systems: Incorporating AQbD principles into existing systems may disrupt workflows and require significant process changes^29-33.

Emerging Trends and Future Directions in AQbD:

Advanced Analytical Technologies: To enhance AQbD implementation, advanced technologies such as automation, high-throughput screening, and real-time data analytics are being integrated. These technologies make method development, monitoring, and optimization more efficient and accurate^34-35. Artificial Intelligence and Machine Learning: AI and machine learning are increasingly used to analyze complex datasets, predict method performance, and optimize the design space. These tools reduce manual work in method development and risk management, improving predictive capabilities. Regulatory Harmonization: Efforts are underway to harmonize regulatory requirements globally, which will facilitate the broader adoption of AQbD and streamline approval processes^36-38. Integration with Quality Management Systems (QMS): AQbD is being integrated with broader quality management systems to promote continuous improvement and better compliance, aligning analytical method development with overall quality objectives. Personalized and Precision Medicine: AQbD is supporting the development of analytical methods for personalized and precision medicine, addressing specific patient needs and conditions. Increased Focus on Data Integrity: There is growing emphasis on data integrity and transparency in method development, ensuring better compliance and confidence in method performance^38-41.

CONCLUSION:

Analytical Quality by Design (AQbD) is a systematic approach to analytical method development that focusses on understanding and managing essential factors to achieve consistent performance and dependability. AQbD entails creating an Analytical Target Profile (ATP), establishing Critical Analytical Attributes (CAAs) and Critical Method Parameters (CMPs), and employing risk assessment methods to control variability and assure robustness. DOE is critical in AQbD for optimising method parameters, defining a design space, and evaluating methods within that space to improve performance and reliability. AQbD-based validation is more dynamic and thorough than previous approaches, with a focus on continuous monitoring, risk management, and lifecycle management to keep procedures effective and compliant. Regulatory authorities want AQbD techniques to be well-documented and scientifically rigorous, adhering to guidelines such as ICH Q8, Q9, and Q10, and proving resilience through extensive validation and performance monitoring. Complexity, data management, regulatory approval, resource limits, and system integration are all common obstacles. Future trends include improvements in analytical technology, artificial intelligence and machine learning, regulatory harmonisation, integration with quality management systems, personalised medicine, and a greater emphasis on data integrity.AQbD offers a structured approach to designing analytical procedures that are resilient and reliable across a variety of situations, resulting in more consistent and accurate findings.By systematically optimising method parameters and defining a design space, AQbD eliminates the need for extensive empirical testing, saving time and money.

By proving a deep understanding of method behavior and making sure methods fulfill quality standards at every stage of their lifespan, AQbD satisfies regulatory obligations. Because AQbD is dynamic, method performance may be continuously monitored and modified, leading to ongoing improvement and flexibility in response to changing demands. In order to improve the reliability and credibility of analytical data—both of which are essential for regulatory submissions and quality assurance—AQbD encourages a strict scientific approach to method development.

In summary, AQbD significantly enhances the development and validation of analytical methods, ensuring they are robust, reliable, and compliant with regulatory standards. Its systematic approach facilitates better understanding, optimization, and management of analytical methods, leading to improved quality and efficiency in the pharmaceutical industry.

ABBREVIATIONS:

AQbD: Analytical Quality by Design QTPP: Quality Target Product Profile EMA: European Medicines Agency

QbD: Quality by Design ICH: International Conference on Harmonisation LOD: Limit of detection

CAA: Critical analytical attributes USP: United State pharmacopeia

CMP: Critical Method parameters RSD: Relative standard deviation

DOE: Design of experiments API: Active Pharmaceutical Ingredients

ATP: Analytical target profile FDA: Food and Drug Administration

ACKNOWLEDGEMENT:

Authors would like to thanks L. J. Department of Pharmaceutical Sciences for helping in preparation of this manuscript.

CONFLICT OF INTEREST:

The authors declare that they have no conflict of interest.

REFERENCES:

1. International Council for Harmonisation (ICH). Q8 (R2) Pharmaceutical Development. ICH. 2009. https://www.ich.org/page/quality-guidelines

2. International Council for Harmonisation (ICH). Q9 Quality risk management. ICH. 2005. https://www.ich.org/page/quality-guidelines

3. International Council for Harmonisation (ICH). Q10 Pharmaceutical quality system. ICH. 2008. https://www.ich.org/page/quality-guidelines

4. Dipti G. Phadtare, Pawar Amol R, R.B. Saudagar. A Brief Review on Quality by Design and Process Analytical Technology. Asian J. Pharm. Ana. 2016; 6(2): 122-130.

5. U.S. Food and Drug Administration (FDA). Guidance for industry: Q8(R2) Pharmaceutical development. FDA. 2009. https://www.fda.gov/media/71537/download

6. Praveen Radhakrishnan, Shinu Chacko. Risk Management in Pharmaceutical Development: A Short Review. Asian J. Pharm. Res. 2018; 8(3): 185-190

7. U.S. Food and Drug Administration (FDA). Guidance for industry: Q9 Quality risk management. FDA. 2006. https://www.fda.gov/media/72246/download

8. A. Suneetha, B. Chandra Sekhar, K. Sudheer Babu. DOE Assisted RP-HPLC Method Development and Validation for Estimation of L-Cysteine and Cystine with Dansyl Chloride derivatization in Presence of Amino Acid Mixture. Asian Journal of Pharmaceutical Analysis. 2022; 12(1): 35-2.

9. U.S. Food and Drug Administration (FDA). Guidance for industry: Q10 Pharmaceutical quality system. FDA. 2009. https://www.fda.gov/media/71539/download

10. European Medicines Agency (EMA). Guideline on quality by design for drug substance and drug product. EMA. 2009. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-design-drug-substance-drug-product_en.pdf

11. Prerana Musale, S. D. Mankar. Quality by Design Approch Based in Analytical Method Validation. Asian Journal of Pharmaceutical Analysis. 2023; 13(3): 190-6.

12. Nash R, Wachter JD. Pharmaceutical process validation: An international validation guide. CRC Press; 2003. ISBN: 9780849304694.

13. U.S. Food and Drug Administration (FDA). Guidance for industry: Analytical procedures and methods validation for drugs and biologics. FDA. 2015. https://www.fda.gov/media/87801/download

14. Harris DC. Quantitative chemical analysis. W.H. Freeman and Company; 2015. ISBN: 9781319110145.

15. Kirkland JJ, Boulanger B, Dagnall R, et al. Method development and validation for the pharmaceutical industry. CRC Press; 2015. ISBN: 9780367335353.

16. Teng W, Huang X, Liu S, et al. Application of Quality by Design (QbD) in analytical method development. J Pharm Sci. 2013; 102(9): 3114-3131. doi:10.1002/jps.23555

17. Pallavi M. Patil, Vitthal V. Chopade, Surbhi C. Gupta. Analytical Quality by Design (QbD) Approach for Development and Validation of HPLC Method for Acyclovir: Application Degradation Kinetics. Research Journal of Pharmacy and Technology. 2023; 16(8): 3691-6. doi: 10.52711/0974-360X.2023.00607

18. Bhupendra Shrestha, Hema Basnett, P Mohan Raj, Sita Sharan Patel, Mrinmay Das, Neelesh Kumar Verma. Process Analytical Technology: A Quality Assurance Tool. Research J. Pharm. and Tech. 2009; 2(2): 225-227.

19. Cameron R, Mehta M. Quality by Design for analytical methods: Implementation of QbD principles in analytical method development and validation. J Pharm Biomed Anal. 2015; 105: 44-51. doi:10.1016/j.jpba.2014.11.014

20. Yogita M. Kolekar. Understanding of DoE and its advantages in Pharmaceutical development as per QbD Approach. Asian J. Pharm. Tech. 2019; 9 (4): 271-275.

21. Yogita M. Kolekar. Understanding of DoE and its advantages in Pharmaceutical development as per QbD Approach. Asian J. Pharm. Tech. 2019; 9 (4): 271-275.

22. Desai PM, Moffat AC, Wells T. Recent advances in Analytical Quality by Design (AQbD) and its applications in method development. Anal Chem. 2016; 88(20): 10452-10460. doi:10.1021/acs.analchem.6b03064

23. Ashu Mittal, Shikha Parmar, Sadaf Jamal Gilani, Syed Sarim Imam, Mohamad Taleuzzaman. Optimization and Validation for Simultaneous Estimation of Citicoline and Piracetam in bulk and tablet formulations using RP-HPLC method: Analytical quality by design approach. Asian J. Research Chem. 2017; 10(2): 198-205.

24. Deng X, Cai J, Wang H, et al. Application of Quality by Design (QbD) principles to analytical method development. Anal Chim Acta. 2017; 985: 1-13. doi:10.1016/j.aca.2017.07.040

25. Paz R, Morin S, Baisden R, et al. Quality by Design (QbD) for analytical methods: A practical approach. Pharm Res. 2017; 34(2): 406-420. doi:10.1007/s11095-017-2248-8

26. Singh S, Kapoor V, Saini N. Principles of Quality by Design in analytical method development. Pharm Technol Eur. 2018; 30(6): 42-50. https://www.pharmaceutical-technology.com/articles/principles-quality-design-analytical-method-development/

27. Ghorbani M, Chang R, Davison R, et al. Analytical Quality by Design (AQbD): From theory to practice. Drug Dev Ind Pharm. 2018; 44(9): 1472-1481. doi:10.1080/03639045.2018.1489397

28. Pérez A, Saurina J. Application of design of experiments (DOE) in analytical method development: A case study. J Chromatogr A. 2019; 1608: 460-470. doi:10.1016/j.chroma.2019.460027

29. Sk.Mastanamma, P. Saidulu. B. Srilakshmi, N. Ramadevi, D. Prathyusha, M. Vidya Rani. Analytical Quality by Design Approach for the Development of UV-Spectophotometric method in the Estimation of Tenofovir Alafenamide in bulk and its Laboratory Synthetic Mixture. Research J. Pharm. and Tech. 2018; 11(2): 499-503. doi: 10.5958/0974-360X.2018.00091.4

30. Khan MF, Ali M, Patel S. Risk-based approach to method validation: The role of AQbD in analytical method development. Pharm Dev Technol. 2020; 25(3): 381-391. doi:10.1080/10837450.2020.1837265

31. Gonzalez J, Fernandez L, Ramirez P. The role of Quality by Design in the development of analytical methods. J Pharm Innov. 2021;16(1):1-10. doi:10.1007/s12247-021-09586-5

32. Miller GA, Jankowski T. Understanding the impact of AQbD on analytical method lifecycle management. Qual Assur J. 2021; 27(4): 413-426. doi:10.1002/qaj.407

33. Kumar V, Sharma A. Challenges in implementing Analytical Quality by Design (AQbD) in pharmaceutical industry. Pharm Ind Rev. 2022; 12(2): 38-47. https://www.pharmaindustryreview.com/article/challenges-implementing-aqbd-pharmaceutical-industry

34. Jaiswal A, Gupta P, Singh S. Advancements in Quality by Design for analytical methods: A comprehensive review. Curr Pharm Anal. 2022; 18(1): 1-16. doi:10.2174/15734137226662107151357

35. Bishop R, Brown C, Yoon H. Case studies in AQbD: Implementation and regulatory perspectives. Regul Aff J. 2022; 32(3): 185-195. https://www.regulatoryaffairsjournal.com/case-studies-aqbd

36. Sharma P, Patel S. Future directions in Analytical Quality by Design: Emerging trends and technologies. J Pharm Sci. 2023; 112(3): 987-1000. doi:10.1016/j.xphs.2023.01.002

37. Hema B, Anjali Nayak, Sangeetha G, Rosita ruth Carlota, Maria Danish Alwin, Paramita Das. A new RP-HPLC Method Development, Validation and Stability-Indicating Studies of Epalrestat in Bulk Drug by Analytical Quality by Design Approach. Research Journal of Pharmacy and Technology. 2024; 17(9): 4437-2. doi: 10.52711/0974-360X.2024.00685

38. Amitkumar J. Vyas, Nilam M. Visana, Ajay I. Patel, Ashok B. Patel, Nilesh K. Patel, Sunny R. Shah. Analytical Quality by Design in Stress Testing or Stability - Indicating Method. Asian Journal of Pharmaceutical Analysis. 2021; 11(2): 170-8. doi: 10.52711/2231-5675.2021.00029

39. Lee J, Kim J, Park H. Application of design space and risk management in AQbD: A review of recent advances. Pharm Res. 2023; 40(1): 123-134. doi:10.1007/s11095-023-03826-6

40. Patel MK, Singh R, Mehta A. Regulatory considerations in Analytical Quality by Design: A global perspective. Int J Pharm Sci Res. 2023; 14(2): 212-225. doi:10.13040/IJPSR.0975-8232.14(2).212-25

41. Nguyen TH, Smith R. Integration of AQbD into pharmaceutical quality systems: Best practices and challenges. Qual Manag J. 2023; 30(4): 255-268. doi:10.1080/10686967.2023.2213574

Received on 21.12.2024 Revised on 12.04.2025

Accepted on 07.06.2025 Published on 10.02.2026

Available online from February 16, 2026

Research J. Pharmacy and Technology. 2026;19(2):939-945.

DOI: 10.52711/0974-360X.2026.00133

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.